Aldexa Therapeutics to price initial public offering of common stock

Company will sell stock through sole bookrunning manager Aegis Capital

By Devika Patel

Knoxville, Tenn., Jan. 6 - Aldexa Therapeutics, Inc. will price its initial public sale of common stock with a 45-day greenshoe, according to a Form S-1 filed Monday with the Securities and Exchange Commission.

Aegis Capital Corp. is the sole bookrunning manager.

Proceeds will be used for research and development activities, including clinical trials, and for working capital and other general corporate purposes.

The biotechnology company is based in Burlington, Mass. The company's expects its shares will trade on the Nasdaq under the symbol "ALDX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.